CoronaryAtlas logo
CoronaryAtlas
Thrombin-Activatable Fibrinolysis Inhibitor
Pathway / Coagulation & thrombus formation

Thrombin-Activatable Fibrinolysis Inhibitor

CPB2protein

TAFI cross-links fibrin and inhibits plasmin-mediated fibrinolysis, stabilizing the occluding thrombus in Type 1 MI.

Pathway placement
Cascade stepCoagulation & thrombus formation
Confidencemedium
RationaleThrombin-activated inhibitor of fibrinolysis; regulates fibrin breakdown during thrombosis.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000080618

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
84
C — confounder / Type-II
63
A — assay feasibility
68
E — evidence strength
32
T1DI (composite)
13
Specificity differential (R−C)+21.2
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(7)